

Francesco Cosentino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5730282/publications.pdf>

Version: 2024-02-01

214
papers

25,885
citations

19657

61
h-index

6836

155
g-index

223
all docs

223
docs citations

223
times ranked

25367
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
2	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	2.2	2,517
3	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	2.2	1,758
4	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2851-2906.	2.2	1,394
5	Diabetes and Vascular Disease. <i>Circulation</i> , 2003, 108, 1527-1532.	1.6	1,249
6	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	2.2	1,144
7	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 1425-1435.	27.0	927
8	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. <i>European Heart Journal</i> , 2013, 34, 2436-2443.	2.2	870
9	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 148.	6.1	625
10	High Glucose Increases Nitric Oxide Synthase Expression and Superoxide Anion Generation in Human Aortic Endothelial Cells. <i>Circulation</i> , 1997, 96, 25-28.	1.6	624
11	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. <i>Atherosclerosis</i> , 2015, 241, 507-532.	0.8	587
12	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	7.1	434
13	Diabetes and Vascular Disease. <i>Circulation</i> , 2003, 108, 1655-1661.	1.6	397
14	High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells. <i>Circulation</i> , 2003, 107, 1017-1023.	1.6	389
15	Statin Prevents Tissue Factor Expression in Human Endothelial Cells. <i>Circulation</i> , 2002, 105, 1756-1759.	1.6	320
16	Ageing, metabolism and cardiovascular disease. <i>Journal of Physiology</i> , 2016, 594, 2061-2073.	2.9	311
17	Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. <i>European Journal of Cancer</i> , 2016, 59, 22-33.	2.8	297
18	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <i>European Heart Journal</i> , 2013, 34, 2444-2452.	2.2	282

#	ARTICLE	IF	CITATIONS
19	Deletion of p66 ^{shc} Gene Protects Against Age-Related Endothelial Dysfunction. <i>Circulation</i> , 2004, 110, 2889-2895.	1.6	276
20	Atherosclerosis and the Two Faces of Endothelial Nitric Oxide Synthase. <i>Circulation</i> , 1998, 97, 108-112.	1.6	274
21	Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 775-789.	2.8	245
22	Tetrahydrobiopterin and Dysfunction of Endothelial Nitric Oxide Synthase in Coronary Arteries. <i>Circulation</i> , 1995, 91, 139-144.	1.6	243
23	Genetic deletion of p66 ^{Shc} adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5217-5222.	7.1	229
24	Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1657-1664.	2.5	220
25	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	1.8	220
26	Gene Silencing of the Mitochondrial Adaptor p66 ^{Shc} Suppresses Vascular Hyperglycemic Memory in Diabetes. <i>Circulation Research</i> , 2012, 111, 278-289.	4.5	219
27	Tetrahydrobiopterin Improves Endothelial Function in Patients with Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 173-178.	1.9	201
28	Anatomic Heterogeneity of Vascular Aging. <i>Hypertension</i> , 1997, 30, 817-824.	2.7	178
29	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 133-173.	2.0	173
30	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association – European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	2.2	171
31	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). <i>American Heart Journal</i> , 2018, 206, 11-23.	2.7	171
32	Total laparoscopic hysterectomy versus abdominal hysterectomy with lymphadenectomy for early-stage endometrial cancer: A prospective randomized study. <i>Gynecologic Oncology</i> , 2009, 112, 126-133.	1.4	167
33	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. <i>Cardiovascular Research</i> , 2021, 117, 29-42.	3.8	164
34	Reactive Oxygen Species Mediate Endothelium-Dependent Relaxations in Tetrahydrobiopterin-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 496-502.	2.4	158
35	Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 142, 2205-2215.	1.6	156
36	Final Common Molecular Pathways of Aging and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 622-628.	2.4	155

#	ARTICLE	IF	CITATIONS
37	Tetrahydrobiopterin and endothelial nitric oxide synthase activity. <i>Cardiovascular Research</i> , 1999, 43, 274-278.	3.8	152
38	Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 150-158.	5.1	141
39	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels. <i>Diabetes</i> , 2017, 66, 2472-2482.	0.6	139
40	Non-coronary atherosclerosis. <i>European Heart Journal</i> , 2014, 35, 1112-1119.	2.2	136
41	MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. <i>European Heart Journal</i> , 2016, 37, 572-576.	2.2	136
42	The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2019, 40, 3215-3217.	2.2	132
43	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	7.1	131
44	Insulin Resistance, Diabetes, and Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2014, 16, 419.	4.8	129
45	Assessment of flow-mediated dilation reproducibility. <i>Journal of Hypertension</i> , 2012, 30, 1399-1405.	0.5	125
46	Selective Inhibition of Protein Kinase C ² Prevents Acute Effects of High Glucose on Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells. <i>Circulation</i> , 2004, 110, 91-96.	1.6	120
47	Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. <i>American Journal of Hypertension</i> , 2005, 18, 493-499.	2.0	107
48	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 2814-2821.	3.8	104
49	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 46-52.	11.4	103
50	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. <i>Diabetologia</i> , 2021, 64, 1256-1267.	6.3	103
51	Sodium-glucose cotransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.1	100
52	SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory. <i>Diabetes</i> , 2013, 62, 1800-1807.	0.6	96
53	Deletion of the Activated Protein-1 Transcription Factor JunD Induces Oxidative Stress and Accelerates Age-Related Endothelial Dysfunction. <i>Circulation</i> , 2013, 127, 1229-1240.	1.6	90
54	Oxidized Low-Density Lipoprotein Activates p66 ^{Shc} via Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1, Protein Kinase C ² , and c-Jun N-Terminal Kinase Kinase in Human Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2090-2097.	2.4	87

#	ARTICLE	IF	CITATIONS
55	<i>c-Jun N-Terminal Kinase 2</i> Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative Stress. <i>Circulation</i> , 2008, 118, 2073-2080.	1.6	83
56	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. <i>European Heart Journal</i> , 2015, 36, 817-828.	2.2	75
57	Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. <i>European Heart Journal</i> , 2013, 34, 96-103.	2.2	72
58	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.1	71
59	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate+statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
60	Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial—NCT02324595): a feasibility study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 503.e1-503.e6.	1.3	66
61	Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.1	66
62	Epigenetics and Immunometabolism in Diabetes and Aging. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 257-274.	5.4	63
63	How to Select Early-Stage Cervical Cancer Patients Still Suitable for Laparoscopic Radical Hysterectomy: a Propensity-Matched Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1947-1955.	1.5	63
64	Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective. <i>Atherosclerosis</i> , 2013, 230, 191-197.	0.8	62
65	Endothelial Dysfunction and Stroke. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, S75-S78.	1.9	59
66	Robotic versus laparoscopic radical hysterectomy in early cervical cancer: A case matched control study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 754-759.	1.0	55
67	Glycogen Synthase Kinase-3 Mediates Endothelial Cell Activation by Tumor Necrosis Factor- α . <i>Circulation</i> , 2005, 112, 1316-1322.	1.6	52
68	Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic β_1 -selective receptor blockade. <i>Journal of Hypertension</i> , 2002, 20, 421-428.	0.5	51
69	Role of oxidative stress in endothelial insulin resistance. <i>World Journal of Diabetes</i> , 2015, 6, 326.	3.5	51
70	Pharmacological Mechanisms of Clinically Favorable Properties of a Selective β_1 -Adrenoceptor Antagonist, Nebivolol. <i>Cardiovascular Drug Reviews</i> , 2004, 22, 155-168.	4.1	50
71	Expression of the ageing gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. <i>Atherosclerosis</i> , 2012, 220, 282-286.	0.8	50
72	The role of p66Shc deletion in age-associated arterial dysfunction and disease states. <i>Journal of Applied Physiology</i> , 2008, 105, 1628-1631.	2.5	49

#	ARTICLE	IF	CITATIONS
73	p66Shc protein, oxidative stress, and cardiovascular complications of diabetes: the missing link. <i>Journal of Molecular Medicine</i> , 2009, 87, 885-891.	3.9	49
74	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. <i>JACC: Heart Failure</i> , 2018, 6, 246-256.	4.1	47
75	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc. <i>International Journal of Cardiology</i> , 2018, 268, 179-186.	1.7	47
76	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. <i>European Heart Journal</i> , 2019, 40, 383-391.	2.2	45
77	Telelap ALF-X vs Standard Laparoscopy for the Treatment of Early-Stage Endometrial Cancer: A Single-Institution Retrospective Cohort Study. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 378-383.	0.6	44
78	Near-Infrared Imaging with Indocyanine Green for Detection of Endometriosis Lesions (Gre-Endo) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	0.6	44
79	Alzheimer's disease and endothelial dysfunction. <i>Neurological Sciences</i> , 2010, 31, 1-8.	1.9	43
80	Molecular pathways of arterial aging. <i>Clinical Science</i> , 2015, 128, 69-79.	4.3	42
81	Inhibition of Protein Kinase C β Prevents Foam Cell Formation by Reducing Scavenger Receptor A Expression in Human Macrophages. <i>Circulation</i> , 2008, 118, 2174-2182.	1.6	41
82	Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 52-60.	1.8	41
83	Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. <i>International Journal of Cardiology</i> , 2016, 203, 702-707.	1.7	39
84	Nebivolol Induces NO-Mediated Relaxations of Rat Small Mesenteric But Not of Large Elastic Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, 316-320.	1.9	39
85	High-intensity interval training modulates retinal microvascular phenotype and DNA methylation of p66Shc gene: a randomized controlled trial (EXAMIN AGE). <i>European Heart Journal</i> , 2020, 41, 1514-1519.	2.2	38
86	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020, 127, 1261-1273.	4.5	38
87	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. <i>Cardiovascular Diabetology</i> , 2021, 20, 218.	6.8	38
88	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787761.	2.4	38
89	Cardiac, renal, and metabolic effects of sodium-glucose cotransporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275.	7.1	36
90	Abnormalities of Endothelial Function in the Pathogenesis of Stroke: The Importance of Endothelin. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, S45-S48.	1.9	36

#	ARTICLE	IF	CITATIONS
91	Restoring the Dysfunctional Endothelium. <i>Current Pharmaceutical Design</i> , 2007, 13, 1053-1068.	1.9	35
92	Use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1012-1022.	7.1	33
93	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019, 40, 2907-2919.	2.2	32
94	Effects of blood pressure and glucose on endothelial function. <i>Current Hypertension Reports</i> , 2001, 3, 79-88.	3.5	31
95	Is early stage endometrial cancer safely treated by laparoscopy? Complications of a multicenter study and review of recent literature. <i>Surgical Oncology</i> , 2011, 20, 80-87.	1.6	31
96	Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. <i>Current Hypertension Reports</i> , 2011, 13, 318-324.	3.5	31
97	p66Shc-induced redox changes drive endothelial insulin resistance. <i>Atherosclerosis</i> , 2014, 236, 426-429.	0.8	31
98	Anti-Aging Medicine: Molecular Basis for Endothelial Cell-Targeted Strategies – A Mini-Review. <i>Gerontology</i> , 2011, 57, 101-108.	2.8	30
99	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. <i>International Journal of Cardiology</i> , 2020, 313, 76-82.	1.7	30
100	Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2015, 16, 531-543.	1.6	30
101	Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 324-32.	1.7	30
102	Hypertension, stroke, and endothelium. <i>Current Hypertension Reports</i> , 2005, 7, 68-71.	3.5	29
103	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , 2016, 37, 152-160.	2.2	29
104	Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1062-1068.	1.0	28
105	Pulsatile Stretch Induces Release of Angiotensin II and Oxidative Stress in Human Endothelial Cells: Effects of ACE Inhibition and AT ₁ Receptor Antagonism. <i>Clinical and Experimental Hypertension</i> , 2008, 30, 616-627.	1.3	27
106	Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. <i>European Heart Journal</i> , 2016, 37, 1733-1737.	2.2	27
107	The year in cardiology 2018: prevention. <i>European Heart Journal</i> , 2019, 40, 336-344.	2.2	26
108	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1352-1360.	1.8	26

#	ARTICLE	IF	CITATIONS
109	Ertugliflozin and Slope of Chronic eGFR. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1345-1354.	4.5	26
110	Diabetes and Inflammation. <i>Herz</i> , 2004, 29, 749-759.	1.1	25
111	Impact of Fasting Glycemia and Regional Cerebral Perfusion in Diabetic Subjects. <i>Stroke</i> , 2009, 40, 306-308.	2.0	25
112	Should the Number of Metastatic Pelvic Lymph Nodes Be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?. <i>Cancers</i> , 2020, 12, 1552.	3.7	24
113	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function. <i>Circulation</i> , 2021, 143, 602-605.	1.6	24
114	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1829-1839.	4.4	23
115	p66 Shc as the Engine of Vascular Aging. <i>Current Vascular Pharmacology</i> , 2012, 10, 697-699.	1.7	21
116	Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 149-157.	4.4	21
117	Laparoscopic Management of Abdominal Pregnancy. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 724-725.	0.6	20
118	Long-term evaluation of quality of life and gastrointestinal well-being after segmental colo-rectal resection for deep infiltrating endometriosis (ENDO-RESECT QoL). <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 217-228.	1.7	20
119	Kidney outcomes using a sustained $\geq 40\%$ decline in $\langle \text{scp} \rangle \text{eGFR} \langle / \text{scp} \rangle$: A meta-analysis of $\langle \text{scp} \rangle \text{SGLT2} \langle / \text{scp} \rangle$ inhibitor trials. <i>Clinical Cardiology</i> , 2021, 44, 1139-1143.	1.8	20
120	Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. <i>Journal of Cardiac Failure</i> , 2022, 28, 1050-1062.	1.7	19
121	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 14-23.	2.0	18
122	Physical activity may drive healthy microvascular ageing via downregulation of p66 ^{Shc} . <i>European Journal of Preventive Cardiology</i> , 2020, 27, 168-176.	1.8	18
123	The year in cardiovascular medicine 2020: epidemiology and prevention. <i>European Heart Journal</i> , 2021, 42, 813-821.	2.2	18
124	Hyperglycemia: a bad signature on the vascular system. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 403-6.	1.7	17
125	Vascular Effects of Newer Cardiovascular Drugs: Focus on Nebivolol and ACE-Inhibitors. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, S3-S12.	1.9	16
126	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 136.e1-136.e56.	1.2	15

#	ARTICLE	IF	CITATIONS
127	Investigating the possible impact of peritoneal tumor exposure amongst women with early stage cervical cancer treated with minimally invasive approach. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1090-1097.	1.0	15
128	Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002484.	2.8	14
129	Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>European Heart Journal</i> , 2022, 43, 2931-2945.	2.2	14
130	The Role of Oxidative Stress in Endothelial Dysfunction and Vascular Inflammation. , 2010, , 705-754.		13
131	The year in cardiology: cardiovascular prevention. <i>European Heart Journal</i> , 2020, 41, 1157-1163.	2.2	13
132	Non-Insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451.	3.1	13
133	Diabetes and coronary artery disease: not just a risk factor. <i>Heart</i> , 2020, 106, 1357-1364.	2.9	13
134	Impaired vasorelaxant responses to natriuretic peptides in the stroke-prone phenotype of spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 1998, 16, 151-156.	0.5	12
135	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 377-387.	1.8	12
136	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 432-445.	1.8	11
137	A Multicentric Randomized Trial to Evaluate the ROle of Uterine MANipulator on Laparoscopic/Robotic HYsterectomy for the Treatment of Early-Stage Endometrial Cancer: The ROMANHY Trial. <i>Frontiers in Oncology</i> , 2021, 11, 720894.	2.8	11
138	Diabetes and ischaemic stroke: a deadly association. <i>European Heart Journal</i> , 2018, 39, 2387-2389.	2.2	10
139	Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 329-330.	2.2	10
140	Aging and endothelial dysfunction. <i>Clinical Hemorheology and Microcirculation</i> , 2007, 37, 143-7.	1.7	10
141	Arterial-enteric fistula after pelvic lymphadenectomy in secondary cytoreductive surgery for recurrent ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 1049-1056.	0.9	9
142	Feasibility and safety of two different surgical routes for the eradication of recto-vaginal endometriosis with vaginal mucosa infiltration (Endo-vag study). <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 1050-1056.	2.8	9
143	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. <i>Cardiovascular Diabetology</i> , 2021, 20, 75.	6.8	9
144	Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). <i>Diabetes Therapy</i> , 2022, 13, 795-810.	2.5	9

#	ARTICLE	IF	CITATIONS
145	Advanced glycation endproducts and plaque instability: a link beyond diabetes. <i>European Heart Journal</i> , 2014, 35, 1095-1097.	2.2	8
146	Sodium-glucose Cotransporter 2 Inhibitors, All-cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-analysis and Meta-regression. <i>Journal of the American Heart Association</i> , 2021, 10, e019918.	3.7	8
147	Vascular repair and regeneration in cardiometabolic diseases. <i>European Heart Journal</i> , 2022, 43, 450-459.	2.2	8
148	Long-Term Tolerability and Efficacy of the Fixed Combination of Manidipine and Delapril in Patients with Essential Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003, 10, 81-86.	2.2	7
149	The clinical relevance of dysfunctional HDL in patients with coronary artery disease: A 3-year follow-up study. <i>International Journal of Cardiology</i> , 2012, 158, 158-160.	1.7	7
150	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015, 199, 415-423.	1.7	7
151	Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 845-852.	2.5	7
152	The year in cardiovascular medicine 2021: diabetes and metabolic disorders. <i>European Heart Journal</i> , 2022, 43, 263-270.	2.2	7
153	Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial. <i>American Journal of Nephrology</i> , 2022, 53, 516-525.	3.1	7
154	Nitric Oxide Release Is Impaired in Hypertensive Individuals With Familial History of Stroke. <i>American Journal of Hypertension</i> , 2006, 19, 1213-1216.	2.0	6
155	Glucose-lowering treatment in cardiovascular and peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018, 39, 86-98.	3.5	6
156	Sirtuin 1/soluble guanylyl cyclase: a nitric oxide-independent pathway to rescue ageing-induced vascular dysfunction. <i>Cardiovascular Research</i> , 2019, 115, 485-487.	3.8	6
157	The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns. <i>European Heart Journal</i> , 2020, 41, 3419-3420.	2.2	6
158	Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature. <i>Annals of Translational Medicine</i> , 2020, 8, 1687-1687.	1.7	6
159	Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure. <i>European Heart Journal</i> , 2022, 43, 2994-2996.	2.2	6
160	Nitric Oxide and Endothelial Regulation of Vascular Tone. <i>Methods in Neurosciences</i> , 1996, , 215-227.	0.5	5
161	Exercise-induced improvement of microvascular phenotype and reprogramming of p66Shc DNA methylation. <i>European Heart Journal</i> , 2019, 40, 3948-3949.	2.2	5
162	Laparotomy approach to sentinel lymph node detection in ovarian cancer using a near-infrared fluorescent system camera with indocyanine green dye. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 712-713.	2.5	5

#	ARTICLE	IF	CITATIONS
163	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from <scp>VERTIS CV</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1114-1122.	4.4	5
164	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from <scp>VERTIS CV</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2022, , .	4.4	5
165	Statins Blunt Thrombin-induced Down-regulation of Endothelial Nitric Oxide Synthase Expression in Human Endothelial Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 663-667.	1.9	4
166	Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. <i>European Heart Journal</i> , 2009, 30, 1301-1304.	2.2	4
167	Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. <i>American Journal of Medicine</i> , 2017, 130, 1068-1075.	1.5	4
168	High awareness of diabetes as a key cardiovascular risk factor among healthcare professionals but suboptimal treatment: Results from a survey of the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2020, , 2047487320911845.	1.8	4
169	Laparoscopic treatment of ovarian granulosa cells tumor developed in the pelvic anterior preperitoneal space 20 years after laparotomic salpingo-oophorectomy: case report and review of literature. <i>Gynecological Endocrinology</i> , 2020, 36, 926-928.	1.7	4
170	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108870.	2.8	4
171	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedicalscience</i> , 2020, 14, 998.	1.1	4
172	Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial. <i>Kidney International Reports</i> , 2022, 7, 1782-1792.	0.8	4
173	HN-10200 causes endothelium-independent relaxations in isolated canine arteries. <i>Cardiovascular Drugs and Therapy</i> , 1992, 6, 159-165.	2.6	3
174	Protocol for an Observational Blood Pressure Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004, 11, 11-14.	2.2	3
175	Diabetes and Endothelial Dysfunction. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 5-10.	2.2	3
176	Prevalence of "Borderline" Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 43-51.	2.2	3
177	Is there any memory effect of blood pressure lowering in diabetes?. <i>International Journal of Cardiology</i> , 2011, 151, 384-385.	1.7	3
178	The year in cardiology 2017: prevention. <i>European Heart Journal</i> , 2018, 39, 345-353.	2.2	3
179	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 139-140.	11.4	3
180	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2021, 17, e618-e630.	3.2	3

#	ARTICLE	IF	CITATIONS
181	Antihypertensive effect and end-organ protection of flavonoids: some insights, more questions. <i>Journal of Hypertension</i> , 2002, 20, 1721-1724.	0.5	2
182	Effects of Olmesartan on Endothelial Function. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 221-227.	2.2	2
183	Epidemiology, Definition, and Diagnosis of Diabetes Mellitus. , 2015, , 3-12.		2
184	The environment, epigenetic landscape and cardiovascular risk. <i>Cardiovascular Research</i> , 2019, 115, e147-e150.	3.8	2
185	Cardio-diabetology: The new "sweetheart"™ in cardiovascular prevention. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 5-6.	1.8	2
186	Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer. <i>Chemotherapy</i> , 2020, 65, 54-57.	1.6	2
187	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 28-33.	4.0	2
188	Guideline Development for Medical Device Technology: Issues for Consideration. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1698-1710.	2.2	2
189	Nifedipine inhibits superoxide production induced by pulsatile stretch in human aortic endothelial cells. <i>American Journal of Hypertension</i> , 2000, 13, S34.	2.0	1
190	AT2-mediated vasorelaxation by angiotensin II in SHR chronically treated with losartan. <i>American Journal of Hypertension</i> , 2002, 15, A13.	2.0	1
191	Do COX-2 inhibitors really prevent hypertension and proteinuria? Another brick in the wall for the COX-2 inhibition and cardiovascular disease controversy. <i>Journal of Hypertension</i> , 2003, 21, 501-503.	0.5	1
192	Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 17-22.	2.2	1
193	Mechanisms of Cardiovascular Aging. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2013, 2, 275-283.	0.7	1
194	Obesity-induced impairment of pluripotent stem cells: novel insights into vascular repair strategies. <i>European Heart Journal</i> , 2019, 40, e11-e13.	2.2	1
195	Mechanisms of Diabetic Atherosclerosis. , 2015, , 23-33.		1
196	The Role of eNOS in Vascular Diseases. , 2007, , 227-243.		1
197	Viewpoint: Climbing the academic ladder in Italy. <i>Circulation</i> , 2006, 114, f193-4.	1.6	1
198	Oxidative Stress and Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003, 10, 27-33.	2.2	0

#	ARTICLE	IF	CITATIONS
199	Evolving Pathophysiological Perspectives in Endothelial Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 47-53.	2.2	0
200	The Renin-Angiotensin System, Capri 2005. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 91-108.	2.2	0
201	Hyperglycemia. , 2015, , 85-100.		0
202	Diabetes and Cardiovascular Disease. , 2015, , 13-21.		0
203	The combination of coronary artery disease and type 2 diabetes: a therapeutic challenge. European Heart Journal Supplements, 2019, 21, C37-C39.	0.1	0
204	CardioScape-II: the need to map cardiovascular funding patterns in Europe. Cardiovascular Research, 2020, 116, 879-881.	3.8	0
205	Prevention and treatment of venous thromboembolism. European Heart Journal Supplements, 2020, 22, C1-C1.	0.1	0
206	SGLT2i: new perspectives in diabetes and kidney disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e4-e4.	3.0	0
207	Antioxidants and Endothelial Function: Human Studies. Developments in Cardiovascular Medicine, 2006, , 279-304.	0.1	0
208	Risk Stratification. , 2015, , 69-83.		0
209	Ischemic Stroke. , 2015, , 189-202.		0
210	Environment, Epigenetic Changes, and Cardiovascular Damage. , 2015, , 35-47.		0
211	Antiplatelet Therapy. , 2015, , 133-144.		0
212	Arterial Hypertension. , 2015, , 115-131.		0
213	The year in cardiology: cardiovascular prevention /The year in cardiology 2019. Revista Romana De Cardiologie, 2020, 30, 20-29.	0.1	0
214	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. Diabetologia, 2022, 65, 908-911.	6.3	0